Healthesystems:

The FDA has approved Enoby™ (denosumab-qdbe) injections as a biosimilar to Prolia® (denosumab) to increase bone mass in those at high risk of fractures.

As the workforce grows older, and as entities such as the WCRI report on the frequency and impacts that degenerative conditions have on claims, awareness of these conditions and the therapies that address them becomes increasingly important.

Read the full article from Healthesystems here.

The WCRI study they reference is Degenerative and Comorbid Conditions in Workers’ Compensation. You can find more information on this study, including details on how to download a copy, on our website.